Released : Jun 30, 2015

RNS Number : 6823R

Tiziana Life Sciences PLC

30 June 2015

 

 

 

 

Tiziana Life Sciences plc

("Tiziana" or "the Company")

 

 

Result of Annual General Meeting

 

London, 30 June 2015 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, today held its Annual General Meeting, at which all resolutions were duly passed.

 

Voting on the resolutions was as follows:-

 

 

Resolution		For	Against	Withheld
1	Annual Report & Accounts	63,305,178	-	501
2	Re-appointment of auditor	63,305,679	-	-
3	Re-appointment of director	63,305,679	-	-
4	Re-appointment of director	63,305,679	-	-
5	Authority to allot Shares	63,305,617	33	29
6	Dis-application of pre-emption rights	63,305,309	369	1

 

 

 

Contacts:

 

Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder	+44 (0)20 7493 2853
Cairn Financial Advisers LLP (Nominated advisor) Liam Murray / Avi Robinson	+44 (0)20 7148 7900
Beaufort Securities Limited (Broker) Saif Janjua	+44 (0)20 7382 8300
FTI Consulting Simon Conway / Rob Winder / Natalie Garland-Collins	+44 (0)20 3727 1000

 

 

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology.

 

In January 2015, the Company entered into an exclusive licence from Nerviano Medical Sciences relating to milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma in patients previously treated with chemotherapy.

 

The Company also in-licensed another clinical asset in December 2014 from Novimmune.  Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II asset has potential application in a wide range of autoimmune and inflammatory diseases, such as multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 

Tiziana Life Sciences' research team has discovered that Bcl-3 has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility. Tiziana has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

RAGSDWFFSFISELM